Tumour exosomes display differential mechanical and complement activation properties dependent on malignant state: implications in endothelial leakiness
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background: Exosomes have been implicated in tumour progression and metastatic spread. Little is known of the effect of mechanical and innate immune interactions of malignant cell‐derived exosomes on endothelial integrity, which may relate to increased extravasation of circulating tumour cells and, therefore, increased metastatic spread. Methods: Exosomes isolated from non‐malignant immortalized HCV‐29 and isogenic malignant non‐metastatic T24 and malignant metastatic FL3 bladder cells were characterized by nanoparticle tracking analysis and quantitative nanomechanical mapping atomic force microscopy (QNM AFM) to determine size and nanomechanical properties. Effect of HCV‐29, T24 and FL3 exosomes on human umbilical vein endothelial cell (HUVEC) monolayer integrity was determined by transendothelial electrical resistance (TEER) measurements and transport was determined by flow cytometry. Complement activation studies in human serum of malignant and non‐malignant cell‐derived exosomes were performed. Results: FL3, T24 and HCV‐29 cells produced exosomes at similar concentration per cell (6.64, 6.61 and 6.46×10 4 exosomes per cell for FL3, T24 and HCV‐29 cells, respectively) and of similar size (120.2 nm for FL3, 127.6 nm for T24 and 117.9 nm for HCV‐29, respectively). T24 and FL3 cell‐derived exosomes exhibited a markedly reduced stiffness, 95 MPa and 280 MPa, respectively, compared with 1,527 MPa with non‐malignant HCV‐29 cell‐derived exosomes determined by QNM AFM. FL3 and T24 exosomes induced endothelial disruption as measured by a decrease in TEER in HUVEC monolayers, whereas no effect was observed for HCV‐29 derived exosomes. FL3 and T24 exosomes traffic more readily (11.6 and 21.4% of applied exosomes, respectively) across HUVEC monolayers than HCV‐29 derived exosomes (7.2% of applied exosomes). Malignant cell‐derived exosomes activated complement through calcium‐sensitive pathways in a concentration‐dependent manner. Conclusions: Malignant (metastatic and non‐metastatic) cell line exosomes display a markedly reduced stiffness and adhesion but an increased complement activation compared to non‐malignant cell line exosomes, which may explain the observed increased endothelial monolayer disruption and transendothelial transport of these vesicles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver
Costa-Silva, B., Aiello, N. M., Ocean, A. J., Singh, S., Zhang, H., Thakur, B. K., Becker, A., Hoshino, A., Mark, M. T., Molina, H., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3169 · Cited by 2,692 · cited 1×
“(12,13) beyond that of an auto/paracrine action at the”
BackgroundCrossing the endothelial barrier during metastasis
Reymond, N., d'Água, B. B., & Ridley, A. J. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3628 · Cited by 922 · cited 2×
“The predominant mechanism of extravasation by CTCs is by paracellular transport through the endothelium (30).”
BackgroundHost Matrix Modulation by Tumor Exosomes Promotes Motility and Invasiveness
Mu, W., Rana, S., & Zöller, M. (2013) · Neoplasia · doi:10.1593/neo.13786 · Cited by 248
Cited by
Welsh, J. A., Goberdhan, D. C. I., O'Driscoll, L., Buzas, E. I., Blenkiron, C., Bussolati, B., Cai, H., Di Vizio, D., Driedonks, T. A. P., Erdbrügger, U., et al. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12404 · Cited by 4,663
Extracellular vesicles for drug delivery.
Vader, P., Mol, E. A., Pasterkamp, G., & Schiffelers, R. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.02.006 · Cited by 1,319
van der Koog, L., Gandek, T. B., & Nagelkerke, A. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202100639 · Cited by 418
Challenges in the development and establishment of exosome-based drug delivery systems
Wang, J., Chen, D., & Ho, E. A. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.10.020 · Cited by 382
Signal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 379
Lin, S., Yu, Z., Chen, D., Wang, Z., Miao, J., Li, Q., Zhang, D., Song, J., & Cui, D. (2020) · Small · doi:10.1002/smll.201903916 · Cited by 353
Nanoparticles and innate immunity: new perspectives on host defence
Boraschi, D., Italiani, P., Palomba, R., Decuzzi, P., Duschl, A., Fadeel, B., & Moghimi, S. M. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.013 · Cited by 310
Self-citation
Metadata
- Authors
- Whitehead, B., Wu, L., Hvam, M. L., Aslan, H., Dong, M., Dyrskjøt, L., Ostenfeld, M. S., Moghimi, S. M., & Howard, K. A.
- Venue
- Journal of Extracellular Vesicles
- Publisher
- Wiley
- Published
- 2015-01
- Volume
- 4
- Issue
- 1
- Pages
- 29685-29685
- ISSN
- 2001-3078 (ISSN-L)
- OpenAlex
- W2204009675
- Cited by
- 110
- References
- 3
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.